NATCO PHARMA LTD. Intrinsic Value
NATCOPHARM · Healthcare · Current price ₹839
Is NATCO PHARMA LTD. undervalued?
DocStoX estimates the fair value of NATCO PHARMA LTD. at ₹1,158 per share, versus the current market price of ₹839. That puts the stock about +38.1% below our fair-value estimate, which we read as "Buy". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹653), Relative P/E (₹2,401), Graham floor (₹958), Analyst target (₹1,003). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹653 (bear) to ₹1,158 (base) to ₹2,401 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹839 versus an intrinsic value of ₹1,158, NATCO PHARMA LTD. currently offers +38.1% of margin.
More on NATCO PHARMA LTD.
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.